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Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and
allogeneic stem cell transplantation. Pharmacologically enforced egress of hematopoietic stem cells from BM, or mobilization,
has been achieved by directly or indirectly targeting the CXCL12/CXCR4 axis. Shortcomings of the standard mobilizing agent,
granulocyte colony-stimulating factor (G-CSF), administered alone or in combination with the only approved CXCR4 antagonist,
Plerixafor, continue to fuel the quest for new mobilizing agents. Using Protein Epitope Mimetics technology, a novel peptidic CXCR4
antagonist, POL5551, was developed. In vitro data presented herein indicate high afﬁnity to and speciﬁcity for CXCR4. POL5551
exhibited rapid mobilization kinetics and unprecedented efﬁciency in C57BL/6 mice, exceeding that of Plerixafor and at higher
doses also of G-CSF. POL5551-mobilized stem cells demonstrated adequate transplantation properties. In contrast to G-CSF,
POL5551 did not induce major morphological changes in the BM of mice. Moreover, we provide evidence of direct POL5551
binding to hematopoietic stem and progenitor cells (HSPCs) in vivo, strengthening the hypothesis that CXCR4 antagonists mediate
mobilization by direct targeting of HSPCs. In summary, POL5551 is a potent mobilizing agent for HSPCs in mice with promising
therapeutic potential if these data can be corroborated in humans.
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INTRODUCTION
Mobilization of hematopoietic stem and progenitor cells (HSPCs)
describes their enforced egress from the bone marrow (BM), their
natural place of residence in post-natal mammals, into the
peripheral blood (PB). HSPC mobilization occurs in response to a
wide variety of physiological or pharmacological stimuli, such as
intense physical exercise, infection or inﬂammation, and admin-
istration of cytokines or chemotherapy.
1–3 The clinically most
relevant mobilizing agent, granulocyte colony-stimulating factor
4,5
(G-CSF), promotes mobilization by a complex chain of indirect
convergent cellular and molecular events including interference
with the CXCL12/CXCR4 axis.
6,7 The 5-day course of G-CSF
stimulation required for optimal HSPC mobilization
5,8,9 results in
substantial variability in mobilization efﬁciency.
10 Added to the
adverse effects of G-CSF,
11–15 such as signiﬁcant BM disruption
16–18
and the lingering threat of adverse genetic events induced by
G-CSF,
19,20 these shortcomings have driven the quest for
alternative mobilizing agents devoid of some of these inherent
disadvantages. Direct targeting of CXCR4 with small molecule
antagonists has been used to mobilize HSPCs, most prominently
with the bicyclam antagonist Plerixafor.
21–24 However, CXCR4
inhibitors available to date have proven too weak for efﬁcient
clinical mobilization when given as a single agent.
22,24
CXCR4-deﬁcient hematopoiesis is characterized by a severe
HSPC retention defect in the BM that manifests as constitutive
mobilization.
25 This phenotype suggests that the cellular target of
CXCR4 antagonists that results in HSPC egress from marrow is the
HSPC proper. Indeed, this mechanism has been assumed by
many;
22,26,27 however, direct evidence of this hypothesis has been
lacking and recently published data potentially challenge this
notion.
28
We here report on a novel, potent and highly selective CXCR4
antagonist, POL5551, which was developed using the Protein
Epitope Mimetics technology.
29 Using in vitro and in vivo assays,
we explored in mice the potential of POL5551 as an HSPC-
mobilizing agent. Using labeled compound, we also sought
to identify the cellular target of CXCR4 antagonist-mediated
mobilization.
MATERIALS AND METHODS
Mice
C57BL/6 wild-type (CD45.2) mice purchased from Janvier (Le Genest-
Saint-Isle, France) or Charles River Laboratories (Sulzfeld, Germany) were
used for most experiments. B6.SJL-Ptprc
aPep3
b/BoyJ (CD45.1, Charles River
Laboratories) and F1-hybrid mice (CD45.1/2) were used for engraftment
experiments. B6.SJL-Ptprc
aPep3
b/BoyJ and DBA/2 mice (Janvier) were used
for some mobilization experiments. Animals were housed at the Johann
Wolfgang Goethe-University Medical School vivarium under non-SPF
conditions, with autoclaved chow and water ad libitum. Following lethal
irradiation (1 9.5Gy, except for homing assays, where 1 12.5Gy were
used, using a Cesium source with a dose rate of 1Gy/min) and
transplantation, mice were kept on antibiotic medication, 0.025% Baytril
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www.nature.com/leu(Bayer, Leverkusen, Germany) p.o. in drinking water. All procedures were
approved by the municipal government (Darmstadt, Germany) and the
institutional animal care and use committee, in agreement with the
Association for Assessment and Accreditation of Laboratory Animal Care
(AAALAC) guidelines.
Cells
The murine Ao.o1 T cell line,
30 a kind gift from Dr Franc¸oise Bachelerie
(Unite ´ d’Immunologie Virale, Institut Pasteur, Paris, France), was
engineered to overexpress human CXCR4 under a retroviral promoter.
For details see Supplementary Methods. The generated cell line will be
referred to as Ao.o1_hCXCR4 throughout the manuscript.
PB was drawn from the facial vein of the mice. BM cells were recovered
by ﬂushing femurs, tibias or pelvic bones. Spleen cells were isolated by
gentle blunt extrusion from the capsule. For most of the in vitro studies
(migration, F-actin polymerization, ﬂow cytometry, colony assay) as well as
for the homing assay, cells were washed and erythrocytes were lysed with
ammonium chloride lysis buffer (Sigma-Aldrich, St Louis, MO, USA; or BD
Biosciences, San Jose, CA, USA) prior to the assay performance.
Fluorescence-activated cell sorting and analysis
Cell labeling was performed according to standard protocols using
established marker panels for identiﬁcation of different subsets in mouse
hematopoietic tissues. Antibodies used in this study are detailed in
Supplementary Methods. Subsequent acquisition and analysis were
performed on a BD FACSCanto II cytometer with the FACSDiva software
(BD Biosciences). Some data were further analyzed using the FlowJo
software (Tree Star, Inc., Ashland, OR, USA). Cell isolation by ﬂow sorting
was performed on a BD FACS Aria II (BD Biosciences).
Receptor binding studies
Ao.o1_hCXCR4 cells (see above) were used to study occupation of different
receptor domains by the natural ligand of CXCR4, CXCL12, in comparison
to the antagonists Plerixafor and POL5551. A total of 1–2 10
5 cells were
concurrently incubated with CXCL12, Plerixafor or POL5551 (1mM in
phosphate-buffered saline (PBS)/bovine serum albumin, 0.5%, for all) and
one of the two different CXCR4 antibody clones 12G5 (binding to
extracellular loops) or 1D9 (binding to the N-terminus). Controls were
incubated with the antibodies alone or stained with appropriate
immunoglobulin G isotype controls. Incubation was performed at 41C
(to prevent internalization) in the dark for 30min followed by a wash step
and ﬂuorescence-activated cell sorting analysis of the samples.
Migration
Migration of BM or PB cells through 5-mm pore-size transwells (Corning-
Costar, Tewksbury, MA, USA) towards CXCL12 (100ng/ml, Peprotech, Rocky
Hill, NJ, USA or Cell Systems, Kirkland, WA, USA), or control medium
(spontaneous migration), performed as described,
23 was assessed after 4h.
Input cells and cells from the lower chamber were plated into a colony
assay; colony-forming unit culture (CFU-C) migration is expressed as the
percent of migrated CFU-C of total CFU-C contained in the inoculum
(input).
Actin polymerization assays
BM cells preincubated either with medium or POL5551 (1mM) were
stimulated with 100ng/ml CXCL12 at 371C for the indicated time, ﬁxed in
5% formaldehyde (Carl Roth GmbH, Karlsruhe, Germany) and permeabi-
lized with 0.1% saponin (Carl Roth GmbH), as described.
31 F-actin was then
stained with AlexaFluor568-conjugated phalloidin (Molecular Probes,
Eugene, OR, USA) followed by ﬂow cytometric analysis of the relative
staining intensity.
Ca
2þ ﬂux assay
Ca
2þ assay was performed with CXCR4-transfected 300-19 murine pre-B
cells as described in Supplementary Methods.
HSPC mobilization
POL5551 (Polyphor Ltd, Allschwil, Switzerland) was suspended in saline
and either injected as bolus intraperitoneally (i.p.) or intravenously (i.v.)
(0.5–100mg/g body weight) or ﬁlled into continuous-release osmotic
minipumps (model 2001, Alzet, Palo Alto, CA, USA), which were implanted
under general anesthesia into a dorsal subcutaneous pouch. Mono-
biotinylated POL5551 (Polyphor Ltd) was suspended in PBS (Life Technol-
ogies GmbH, Darmstadt, Germany) and injected i.p. rhG-CSF (Granocyte,
Chugai, Frankfurt, Germany) was suspended in dH20 and diluted in saline to
a ﬁnal concentration of 0.5mg/ml for i.p. injection. Mice received G-CSF
injections every 12h at a dose of 100mg/kg for a total of nine doses i.p.,
referred to as ‘standard regimen’ throughout the manuscript. Subsequent
blood withdrawal and/or administration of POL5551 were performed
directly after the last G-CSF injection on day 5. Cyclophosphamide (CY) or
Plerixafor (both from Sigma-Aldrich) were administered as single i.p.
injections at doses of 200mg/kg or 5 and 10mg/kg, respectively.
Mouse model of diabetes
Diabetes was induced in 12-week-old C57BL/6 mice with a single i.p.
injection of 200mg/kg Streptozotocin (Calbiochem, Merck Millipore,
Darmstadt, Germany) dissolved in citrate buffer (pH 4.7–5.3). Blood glucose
levels were measured with a portable glucose meter (Accu-check Aviva,
Roche Diagnostics, Mannheim, Germany). Only animals with glucose
values higher than 300mg/dl were used for mobilization experiments 2–3
weeks post Streptozotocin injection.
Hematopoietic colony assay
For enumeration of CFU-C, aliquots of cells were incubated in duplicate in
commercially available growth-factor-supplemented methyl cellulose
medium for mouse CFU-C (Stem Cell Technologies, Vancouver, BC, USA
or Cell Systems) as described.
23,32 CFU-C (BFU-E, CFU-GM and CFU-GEMM)
were enumerated after 6–8 days.
Progenitor cell homing
Progenitor cell homing efﬁciency was analyzed as described previously.
32
In brief, lethally irradiated (12.5Gy) recipients received i.v. transplants of
mobilized blood or steady-state BM (ssBM) cells suspended in normal
saline. An aliquot of the inoculum was cultured in CFU-C media to quantify
the input. Twenty hours after transplantation recipients were humanely
killed, and blood, spleen and BM CFU-C contents were enumerated using
colony assay. Homing results were evaluated as the fraction of the total
injected CFU-C that homed to BM (assuming that 1 femur represents 1/16
of total BM
33), spleen and blood (assuming 2ml as total blood volume).
Engraftment kinetics
Engraftment of different graft sources was tested in a non-competitive
setting by transplantation of lethally irradiated (9.5Gy) mice (CD45.2) with
suspensions of mobilized blood cells or BM cells (CD45.1) adjusted to
contain B1500–2000 CFU-C/recipient based on the data from earlier
mobilization studies. Complete blood counts were analyzed every 2–4 days
starting on day 12 following transplantation. For complete blood count,
30–40ml of blood were drawn from the facial vein and analyzed on a
hemocytometer (Hemavet 950, Drew Scientiﬁc, Dallas, TX, USA).
Competitive repopulating unit (CRU) assay
To determine the frequency of long-term repopulating HSCs in POL5551
versus G-CSF-mobilized blood, a limiting dilution CRU assay was
performed.
34 Lethally irradiated CD45.2 hosts, 5–10 per group, received
i.v. grafts consisting of limiting volumes (2.5, 5.0 and 10ml) of CD45.1
POL5551 or G-CSF-mobilized blood cells together with 2.5 10
5 CD45.2
BM competitor cells. After 16 weeks, multilineage contribution of the
CD45.1 graft-derived leukocytes was measured using ﬂow cytometry.
Animals with evidence of mobilized blood-derived (that is, CD45.1þ)
Gr1þ, CD11bþ, B220þ and CD3þ cells (X0.5% for each lineage) were
considered positive for donor cell engraftment. CRU (LTRC) frequency was
calculated using the LCALC software (Stem Cell Technologies).
A repopulating unit (RU) assay
35 was performed to directly compare the
repopulating capacity of PB mobilized with different (combinations of)
compounds. Lethally irradiated CD45.2 hosts received transplants
consisting of a small volumes of blood (CD45.1, 6ml for POL5551-,
Plerixafor- or G-CSF-mobilized blood, 1.5ml for blood mobilized with
G-CSFþPOL5551 or G-CSFþPlerixafor) together with 2.5 10
5 CD45.2 BM
competitor cells. After 12 weeks, blood graft-derived RUs were calculated
for the recipient mice by the following formula: RU¼(D C)/(100 D). D is
the percentage of blood-derived B and myeloid cells. C is the number of
RUs cotransplanted with competitor BM (C¼2.5).
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Tissue processing and immunohistochemistry were performed as
described in Supplementary Methods.
Detection of biotinylated POL5551
For the detection of biotinylated POL5551, blood collected in heparin-
coated tubes (Sarstedt AG & Co, Nu ¨mbrecht, Germany) was treated directly
with the crosslinking reagent Bis[sulfosuccinimidyl] suberate (BS
3, Thermo
Fisher Scientiﬁc Inc, Rockford, IL, USA) at a ﬁnal concentration of 5–10mM
(at ﬁrst resuspended in PBS, Life Technologies GmbH). BM was ﬂushed in
PBS and resuspended in fresh 5mM BS
3 solution. Crosslinking was
performed at room temperature for 30min followed by quenching of
the reaction with 15mM Tris-HCl (pH 7.5, Carl Roth GmbH). Subsequent
ﬁxation of the samples was carried out with 5% formaldehyde (Carl Roth
GmbH), followed by staining with streptavidin and anti-CD45 antibody
performed simultaneously in fresh PBS/bovine serum albumin.
Human subjects’ protection
Human cells, which served as the source for CXCR4 mRNA, were from
anonymized leftover materials from quality control samples, used with
permission of the local internal review board (IRB, no. 329/10) in
agreement with the WMA Declaration of Helsinki. Written donor approval
was obtained.
Statistics
Descriptive statistics and Student’s t-tests, with Bonferroni correction
where indicated, were calculated using Excel (Microsoft, Redmond,
WA, USA).
RESULTS
POL5551 is a potent CXCR4 antagonist
We compared binding properties of POL5551 to those of the
natural ligand, the chemokine CXCL12,
36 and the well-
characterized CXCR4 antagonist Plerixafor.
37 Binding of two
CXCR4 antibodies (Abs), clone 12G5 (which binds extracellular
loops 1 and 2
27) and clone 1D9 (which recognizes an epitope
within the N-terminus
27), was tested using ﬂow cytometry after
concurrent incubation of Ao.o1_hCXCR4 cells with Abs and
compounds (Figure 1a and Supplementary Figure S1). In agree-
ment with previous reports, Plerixafor interfered with 12G5
binding without affecting the binding of 1D9.
27,38 By contrast,
CXCL12 blocked the binding of both clones, indicative of its
interaction with both the extracellular loops and the N-terminus,
again in agreement with published data.
38 Similar to Plerixafor,
POL5551 bound to the extracellular loops but not to the
N-terminal moiety recognized by 1D9. This was also conﬁrmed
by the molecular model of a POL5551 analog
39 bound to CXCR4
(Figure 1b).
We next sought to conﬁrm antagonistic properties of POL5551
in functional in vitro assays. Responsiveness of cells pretreated
with either Plerixafor or POL5551 (both at 1mM) to CXCL12 was
assessed by standard chemotaxis and F-actin polymerization
assays. CXCL12-induced transwell migration of ssBM CFU-C (B6%)
was completely blocked by pre-incubation with either of the
CXCR4 inhibitors (Figure 1c). By contrast, whereas POL5551
pretreatment completely abrogated polymerization of F-actin
ﬁlaments following CXCL12 stimulation, Plerixafor did not show an
inhibitory effect in this assay (Figure 1d). A quantitative
comparison of POL5551- and Plerixafor-mediated inhibition of
cellular Ca
2þ-Flux was performed (Figure 1e). The resulting value
of 2–3nM for POL5551 was B200-fold lower than the IC50
concentration determined for Plerixafor (400–600nM). Thus,
except for the chemotaxis assay, which favors slowly acting
antagonists because of the long incubation time (4h) and where
the activity of the antagonists was the same, in vitro performance
of POL5551 as the CXCR4 inhibitor was superior to that of
Plerixafor.
Rapid and potent mobilization of hematopoietic progenitor cells
by POL5551
Time and dose responsiveness of HSPC egress after POL5551
injection were evaluated next in C57BL/6 mice. CFU-C mobilization
after a single bolus injection of POL5551 (5mg/kg, i.p., Figure 2a)
occurred rapidly with a signiﬁcant increase observed at 1h
(1500CFU-C/ml) and a peak reached after 4h (2200CFU-C/ml),
representing a 10- and 14-fold increase, respectively, compared
with baseline circulating CFU-C levels (B160CFU-C/ml).
The majority of mobilized progenitors disappeared from the
circulation quickly thereafter. Peak plasma concentration of the
compound was reached 1h after injection; after 4h, 490% of
POL5551 had been cleared from the circulation (Supplementary
Figure S2A). After i.v. administration of POL5551, mobilization
kinetics were similar to the i.p. treatment, whereas the efﬁciency
was increased by 450%. (Supplementary Figure S2B).
Whole blood count analysis showed a peak of white blood cell
mobilization at 2h after POL5551 injection (Supplementary Figure
S3A). Compared with control groups receiving G-CSF (standard
regimen) or bolus injection of Plerixafor (5mg/kg, i.p.), no
signiﬁcant differences were found in the relative composition of
mature leukocyte subsets in POL5551-mobilized blood. The
frequency of neutrophils was increased in mobilized (most
prominently in G-CSF-mobilized) versus non mobilized blood
(Supplementary Figure S3B). Further analysis of mobilized subsets
conﬁrmed the relative increase in the myeloid fraction
(Gr1þ,M a c 1 þ) in mobilized blood (Supplementary Figure S3C).
No differences in the ratio of cytotoxic T cells and T-Helper cells
were observed (Supplementary Figure S3D).
Injection of escalating doses of POL5551 (0.5–100mg/kg,
Figure 2b and Supplementary Figure S4) resulted in a positive,
non-linear dose response of mobilized CFU-C for the doses tested.
Mobilization achieved with Plerixafor (5mg/kg, i.p.) or the
standard regimen of G-CSF was in the range of what has been
reported previously by us and others.
16,23,40 At doses 45mg/kg,
POL5551 induced HSPC mobilization (2200CFU-C/ml) to
signiﬁcantly higher levels than Plerixafor (1300CFU-C/ml).
Moreover, at doses of 20–30mg/kg, mobilization levels
(2800–4000CFU-C/ml) were comparable to and at higher doses
even exceeded mobilization with G-CSF (3800CFU-C/ml,
Figure 2b, and data not shown).
To assess the magnitude of the difference in mobilization of
C57BL/6 and DBA/2 mice in response to POL5551, we next
evaluated responsiveness of DBA/2 mice to POL5551 (5 and
50mg/kg, i.p.), with G-CSF- and Plerixafor-treated mice as controls.
Indeed, at both doses mobilization with POL5551 was increased
by almost threefold in DBA/2 relative to C57BL/6 mice (Figure 2c)
similar to the relative increase found with Plerixafor between the
two strains. G-CSF mobilized at least six times more CFU-C in
DBA/2 than in C57BL/6 mice.
Streptozotocin-induced diabetic mice (type 1 diabetes
41)
were used as a disease model of G-CSF refractoriness.
POL5551 (30mg/kg)-treated mice were compared with mice
treated with G-CSF (standard regimen) and Plerixafor (10mg/kg,
i.p.). Both CXCR4 antagonists were therefore tested at
equimolar doses. Treatment with all three agents resulted in
markedly decreased (to approximately one-fourth) mobilization
in diabetic as compared with healthy mice (Figures 2b and d).
Addition of either of the CXCR4 inhibitors (30mg/kg for POL5551
and 10mg/kg for Plerixafor) after the ninth G-CSF dose
could rescue diabetes-induced hyporesponsiveness to G-CSF
(Figure 2e).
POL5551 synergizes with G-CSF and CY
Synergistic mobilization by Plerixafor and G-CSF has been
reported for various treatment schedules of both agents.
21,23
We therefore tested whether a POL5551 bolus injection
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G-CSF could similarly enhance mobilization. Mice mobilized with
the combination of G-CSF and Plerixafor (5 or 10mg/kg) served as
controls, with 10mg/kg of Plerixafor and 30mg/kg of POL5551
representing equimolar doses of the inhibitors. In the combined
treatment regimens, mobilization was noticeably enhanced
(Figure 3a).
The combination of POL5551 or Plerixafor with the cytotoxic
agent CY was investigated next. On day 8 after CY injection,
when peak mobilization occurs,
42 addition of a single dose of
POL5551 or Plerixafor (both at 5mg/kg, i.p.) mobilized 450000
or 440000 CFU-C per ml PB, respectively (Figure 3b).
The synergism between CY and POL5551 or Plerixafor was
more pronounced than the combination of CY plus G-CSF
(Figure 3c).
Properties of POL5551-mobilized stem and -progenitor cells
If POL5551 mobilizes HSPCs by directly targeting the CXCR4
receptor, this raises the question whether as a consequence
POL5551-mobilized cells found in circulation can still sense
CXCL12. We therefore performed migration assays with
POL5551-mobilized blood HSPCs (Figure 4a). At both doses
tested (5 and 30mg/kg), POL5551-mobilized CFU-Cs were highly
responsive towards the chemokine signal, more so than
untreated BM and to a similar degree as was also observed for
G-CSF-mobilized blood. All three mobilized specimen had lower
expression of cell adhesion receptors when compared with
ssBM progenitors (Supplementary Table S2). Interestingly,
CXCR4 surface expression on POL5551-mobilized progenitors
was signiﬁcantly higher relative to ssPB (Supplementary
Figure S5).
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Figure 1. POL5551 is a CXCR4 antagonist. (a, b) Analysis of the binding properties of POL5551 to CXCR4. (a) Ao.o1 cells overexpressing human
CXCR4 were incubated with CXCL12, Plerixafor or POL5551 (1mM for all) plus anti-CXCR4 antibody (Ab) clones 12G5 (extracellular loops) or 1D9
(N-terminus). CXCR4 Ab without agonist/antagonists (untreated) or isotypic control Ab (isotype) were used as positive and negative controls.
(b) Structural model demonstrating the interaction of hairpin-shaped peptide POL5551 (in red) with the extracellular loops of CXCR4 (PDB ﬁle
3OE0). (c, d) Effects of POL5551 on in vitro migration and polymerization of F-actin ﬁlaments: BM cells were incubated with PBS/bovine serum
albumin (BSA) or Plerixafor or POL5551 (1mM in PBS/BSA) and then subjected to transwell migration for 4h ((c) mean±s.e.m., n¼3f o r
Plerixafor- or POL5551-treated samples, n¼10 and 13 for spontaneous migration (medium only) and migration towards CXCL12 (100ng/ml),
respectively) or stimulation with CXCL12 (100ng/ml) with subsequent Phalloidin staining (d) mean±s.e.m., n¼3 for Plerixafor- or POL5551-
treated samples, n¼6 for untreated BM. (e) Determination of POL5551 IC50 value: calcium ﬂux response to CXCL12 stimulation. CXCR4-
transfected murine pre-B cells (300-19) were treated with different concentrations of POL5551 or Plerixafor and stimulated with CXCL12. The
resulting percentage of inhibition of CXCL12-induced Calcium ﬂux was used to calculate the IC50 value (n¼20). Representative inhibition
curves from duplicate measurements are shown.
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pathway for efﬁcient homing of HSPCs.
25,43–45 Given the
unprecedented potency of POL5551 as CXCR4 antagonist, we
tested how efﬁciently POL5551 mobilized CFU-C home to the
BM of lethally irradiated recipients by determining the recovery
of donor cells from hematopoietic organs 20h after
transplantation. As shown in Figure 4b, homing of POL5551-
m o b i l i z e dC F U - Cw a sa se f ﬁ c i e n ta st h a to fs s B M .O u rn e x t
experiment consequently addressed whether POL5551-
mobilized progenitors can also provide timely early engraft-
ment. As determined by serial blood count analyses, all three
examined transplant sources, ssBM, as well as G-CSF- or
POL5551-mobilized blood, showed similar kinetics of engraft-
ment in lethally irradiated hosts (Figure 4c).
POL5551 mobilizes CRU
The frequency of long-term RUs in POL5551 bolus-mobilized
blood was quantiﬁed and compared with G-CSF-mobilized blood
using a standard limiting dilution CRU assay.
34 Based on the dose
response studies depicted in Figure 2b, we selected a dose of
POL5551 (30mg/kg, i.p.) that induced CFU-C mobilization in the
range of G-CSF. The proportion of engrafted mice increased with
the volume of transplanted blood (Figure 5a). At the doses used,
POL5551 and G-CSF mobilized CRU into blood at similar
frequencies (47 and 34CRU/ml blood, respectively, Figure 5b).
In addition, a RU assay was performed to directly compare the
RU concentration in blood from mice mobilized with G-CSF,
Plerixafor (10mg/kg, i.p.) or POL5551 (30mg/kg, i.p.), as well as
with G-CSF in combination with Plerixafor or POL5551. The relative
concentration of RU in each of the mobilized specimen replicated
the agents’ (agent combinations’) efﬁciency at CFU-C mobilization
(Supplementary Figure S6).
POL5551 treatment has minimal effects on macrophage and
osteoblast distribution within the BM and endosteal
microenvironments
We previously conﬁrmed that mobilization of HSPC using either
G-CSF or CY, but not Plerixafor, occurs through a mechanism that
initiates collapse of HSC niche cellular components.
17 Using a
similar immunohistochemistry approach, we examined whether
the distribution of mature osteoblasts and macrophages
within the BM and endosteal environment was disturbed by
treatment with POL5551. Observations are reported relative to
saline-treated control samples that exhibited expected cellular
distributions for skeletally mature mice (Figures 6a and b).
In contrast to G-CSF (Figures 6c and d), treatment with POL5551
had no apparent effect on macrophage or osteoblast distribution
within the BM and endosteum. The F4/80þosteomac canopy
(Figure 6e, arrows) covering osteocalcinþ osteoblasts (Figure 6f,
arrows) within the endosteal region was clearly maintained.
Similarly, the distribution and relative number of F4/80þ
macrophages within the BM (Figure 6e) were indistinguishable
from saline-treated mice.
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targeting them directly
By injecting biotin-labeled POL5551 (Bio-POL) into mice and
analyzing BM and blood for Bio-POL binding at time points
preceding mobilization (30min after injection), we sought to
determine whether it directly targets HSPCs. Indeed, Bio-POL was
detected on hematopoietic cells (CD45-positive) in the BM within
30min of i.p. injection (Figure 7a), as well as on circulating
cells (Figure 7b). In addition, POL5551 was detected in BM
ﬂuid samples prepared from treated animals (Supplementary
Figure S7).
DISCUSSION
In this study, in vitro and in vivo properties of the novel CXCR4
antagonist POL5551 as a mobilizing agent were evaluated. The
markedly improved potency of POL5551 compared with Plerixafor
was shown by its superior ability to block CXCL12-induced
responses in vitro and reﬂected in its in vivo efﬁcacy. Dose
escalation of POL5551 as a single mobilizing agent resulted in
mobilization in excess of G-CSF-induced mobilization, which to
our knowledge was not previously achieved by CXCR4 antagonists
in mice. Of note, mobilization with Plerixafor in mice was found to
peak at 5mg/kg
21,23 and could not be tested at doses 410mg/kg
because of its toxicity, whereas POL5551 was well tolerated up to
a dose of 100mg/kg. Contrary to what we previously proposed,
23
these data indicate that the restricted efﬁcacy of Plerixafor in
mice might not be because of the limited size of CXCR4-
antagonist-sensitive HSPC pools, but rather to its limited
potency. Furthermore, in the model of diabetes-induced G-CSF
refractoriness, POL5551 was more effective in mobilizing
progenitors than Plerixafor.
Differences in mobilization response of various mouse inbred
strains—best studied for G-CSF but also noted for other
mobilizing agents—are well documented
46,47 and thought to
correspond to the variable response to G-CSF in humans. By
comparison, C57BL/6 mice are relatively poor mobilizers,
whereas DBA/2 mice respond with considerably stronger
mobilization to various stimuli.
21,47 The rapid mobilization
kinetics of Plerixafor and POL5551 would not allow for prior
HSPC proliferation when given as single injection. The
differences between C57BL/6 and DBA/2 mice in mobilization
response to these CXCR4 inhibitors therefore suggest
strain-speciﬁc differences in mice (presumably modelling
individual-speciﬁc differences in humans) in the ﬁrmness of
CXCL12-mediated stem cell retention or in the relative
microanatomical distribution of the cells within the BM.
Synergistic mobilization by G-CSF and CXCR4 antagonists has
generally been attributed to only partial targeting of the CXCR4/
CXCL12 pathway as well as expansion/relocation of CXCR4
antagonist-mobilizable pools over the course of G-CSF treatment.
1,23
In agreement with previous reports, G-CSF-mediated mobilization
was markedly enhanced by the addition of POL5551. Moreover, the
combination of POL5551 or Plerixafor with the cytotoxic agent CY
resulted in synergistic mobilization in excess of that observed with
G-CSF plus CY, which can be explained by the signiﬁcant overlap in
pathways targeted by G-CSF and CY.
7,48
The RU assay conﬁrmed the relative potency of single agents
as well as the combination of G-CSF with CXCR4 antagonists,
reproducing the CFU-C mobilization pattern associated with
these modalities. Limiting dilution competitive transplantation
assays with POL5551-mobilized blood demonstrated the
presence of CRUs, as experimental evidence of mobilization of
true stem cells. The evidence provided is critically important if
clinical transplantation of POL5551-mobilized stem cell grafts is
planned.
The cellular integrity of the endosteal region was maintained
after treatment with POL5551. These data demonstrating differ-
ential effects on marrow architecture by G-CSF and POL5551 are
not unexpected. The rapid kinetics of CXCR4 antagonists would
likely not allow for signiﬁcant architectural changes in the BM,
and indeed similar data were previously reported with the
CXCR4 antagonist Plerixafor.
17 Nevertheless, given the several-fold
weaker action of Plerixafor, the absence of BM remodeling in
response to POL5551 was not self-evident.
Brisk responsiveness of POL5551-mobilized HSPCs to CXCL12
in vitro is in agreement with reported data on efﬁcient
CXCL12-directed transwell migration as a common property of
all mobilized specimen.
32 The observed efﬁcient homing of
POL5551-mobilized progenitors is consistent with publications
about the homing of CXCR4-deﬁcient or of Plerixafor-mobilized
cells.
21,23,25
It has been assumed that the molecular mechanism of
mobilization of HSPCs by CXCR4 antagonists in vivo is disruption
of the CXCL12/CXCR4 axis at the level of the HSPC, and
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derived from the marrow stroma. However, CXCR4 antagonist-
mobilized HSPCs do respond to CXCL12 in vitro (see above and also
refer to other studies
21,23,27). As a result, it has been recently
hypothesized that CXCR4 antagonists also target the stroma cells,
causing an alteration of the CXCL12 gradient and eliciting HSPC
egress by this indirect mechanism.
28 Proof of either of the
hypotheses hinges on the demonstration of the antagonist
binding to CXCR4 on HSPCs in the BM at early time points after
injection of the compound—that is, prior to mobilization. Detection
of biotin-labeled POL5551 on the surface of hematopoietic cells in
BM of Bio-POL-mobilized animals demonstrated here is the ﬁrst
direct evidence of binding of CXCR4 antagonists to HSPCs in vivo
supporting direct targeting of HSPCs by CXCR4 antagonists as the
mechanism underlying their mobilization. Whether attenuation of
the CXCL12 gradient between the BM and plasma also contributes
to cell egress cannot be excluded.
CONCLUDING REMARKS
In summary, we demonstrate that POL5551 is a fast-acting,
efﬁcient and safe mobilizing agent for immature hematopoietic
cells, including long-term repopulating stem cells. At higher
doses, its potency exceeds that of G-CSF in C57BL/6 mice, which
sheds new light on the size of CXCR4 antagonist-mobilizable
pools. With respect to mechanisms of mobilization by CXCR4
inhibitors, we provide evidence supporting the notion that
mobilization with POL5551 is the result of direct targeting of
CXCR4 on HSPCs in the BM. Provided that the data can be
corroborated in humans, POL5551 possesses promising ther-
apeutic potential alone or in combination with the standard
mobilizing agents.
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Figure 5. Mobilization of CRU by POL5551. CRU frequency in
POL5551 (30mg/kg)-mobilized blood was determined using a CRU
assay and compared with the CRU frequency in G-CSF (standard
regimen)-mobilized blood. Lethally irradiated recipients (n¼5–10
per group) received transplants of 250000 BM competitor cells
(CD45.2) together with indicated limiting volumes of mobilized
blood (CD45.1, 3 pooled donors per experimental group). CRU
engraftment, deﬁned as multilineage engraftment of X0.5% per
lineage was quantiﬁed 16 weeks after transplantation. (a) Percen-
tages of negative mice were plotted against blood volume;
f(x)¼ 3.4709xþ100 (R
2¼0.86) for G-CSF and f(x)¼ 3.7672
xþ100 for POL5551 (R
2¼0.75). The mean CRU (LTRC) frequency
(b) was calculated using Poisson’s statistic (LCALC software, Stem
Cell Technologies) (mean±upper/lower frequency).
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& 2013 Macmillan Publishers Limited Leukemia (2013) 1–10Figure 6. Macrophage and osteoblast distribution within the BM in response to mobilizing agents. Immunohistochemical staining of bone
and BM collected from mice treated with saline (a, b), G-CSF (c, d), bolus POL5551 delivery (e, f). Speciﬁc antibody staining (brown) was
performed using antibodies for F4/80 (left panel) or osteocalcin (right panel) and conﬁrmed by comparison to isotype-matched control
staining within the same experiment (data not shown). All sections were counterstained with hematoxylin (blue nuclei). Images within
treatment groups are from serial sections. Bone matrix is demarked as ‘Bone’ and this text is placed in a similar location in paired images,
providing a landmark reference point. Arrows indicate canopy F4/80þ osteomacs in the left panel or mature osteocalcinþ osteoblasts in the
right panel. Arrowhead in a indicates a resting bone surface F4/80þosteomac. Original magniﬁcation of all images is  40.
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105
0
0
102
102
103
103
104
104
105
105 01 0 2 103 104 105
01 0 2 103 104 105
0
0
102
102
103
103
104
104
105
105
0
20
40
60
80
100
0
20
40
60
80
100
Bio-POL+
Bio-POL+
Bio-POL+
Bio-POL+
Streptavidin-APC
FL1
Streptavidin-APC
Streptavidin-APC
Streptavidin-APC
%
 
o
f
 
M
a
x
%
 
o
f
 
M
a
x
control (PBS)
0.75+/-0.1% 12.5+/-19.5%
1.2+/-0.1% 10.5+/-3.6%
F
L
1
control (PBS) Bio-POL (30 mg/kg)
control (PBS) Bio-POL (30 mg/kg)
Bio-POL (30 mg/kg)
Figure 7. Targeting of hematopoietic cells by POL5551. POL5551 labeled with a single biotin molecule (Bio-POL) was injected i.p. (30mg/kg).
Control mice received PBS. Thirty minutes after the injection, blood and BM CD45þ cells were analyzed for the presence of Bio-POL on their
surface using ﬂuorescence-coupled streptavidin. a and b show representative stainings of blood and BM samples, respectively (mean±s.e.m.,
n¼3, 3 independent experiments).
POL5551, a novel CXCR4 antagonist
D Karpova et al
8
Leukemia (2013) 1–10 & 2013 Macmillan Publishers LimitedCONFLICT OF INTEREST
BR, KP, EC and KD are employees of Polyphor that provided the compound and
partially funded the studies described. The remaining authors declare no conﬂict of
interest.
ACKNOWLEDGEMENTS
We kindly thank Dr Kerstin Mohle from the University of Zurich for providing the
picture of the molecular model; Dr Johann Zimmermann and Dr Guillaume Lemercier
for the biological data; and Michel Schmitt, Marie-Anne Westwood and Caroline Kolopp
for the pharmacokinetic data provided by Polyphor. Studies were funded by Deutsche
Krebshilfe grant 108031, Deutsche Forschungsgemeinschaft grant BO3553/1-1 to HB, a
personal endowment to HB by the late WG Pade and by Polyphor AG. HB is a member
of the LOEWE Cell and Gene Therapy Frankfurt faculty, funded by the Hessian Ministry
of Higher Education, Research and the Arts ref. no. III L 4-518/17.004 (2010). JPL is
supported by the Senior Research Fellowship (#1044091) from the National Health and
Medical Research Council of Australia.
AUTHOR CONTRIBUTIONS
DK, KD, GS, DC, EW, MS and AP performed experiments. DK, JPL, BR, KP, EC, KD
and HB planned and analyzed experiments. DK and HB wrote the paper. HB
bears the overall responsibility for the studies. All authors discussed,
commented on and approved the ﬁnal version of the manuscript.
REFERENCES
1 Bonig H, Papayannopoulou T. Hematopoietic stem cell mobilization: updated
conceptual renditions. Leukemia 2012; 27: 24–31.
2 Velders GA, Fibbe WE. Involvement of proteases in cytokine-induced
hematopoietic stem cell mobilization. Ann N Y Acad Sci 2005; 1044: 60–69.
3 Ratajczak MZ. Spotlight series on stem cell mobilization: many hands on the ball,
but who is the quarterback? Leukemia 2010; 24: 1665–1666.
4 Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM.
Peripheral blood stem cell donation: an analysis from the International Bone
Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow
Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689–692.
5 Nervi B, Link DC, Dipersio JF. Cytokines and hematopoietic stem cell mobilization.
J Cell Biochem 2006; 99: 690–705.
6 Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem
and progenitor mobilization. Leukemia 2011; 25: 211–217.
7 Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the
CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization
induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111: 187–196.
8 Anderlini P, Przepiorka D, Huh Y, Lauppe J, Miller P, Sundberg J et al. Duration
of ﬁlgrastim mobilization and apheresis yield of CD34þ progenitor cells and
lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol
1996; 93: 940–942.
9 Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M et al. Harvesting and
enrichment of hematopoietic progenitor cells mobilized into the peripheral blood
of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF)
or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85:
275–282.
10 Mueller MM, Bialleck H, Bomke B, Brauninger S, Varga C, Seidl C et al. Safety
and efﬁcacy of healthy volunteer stem cell mobilization with ﬁlgrastim G-CSF
and mobilized stem cell apheresis: results of a prospective longitudinal 5-year
follow-up study. Vox Sang 2012; 104: 46–54.
11 Akizuki S, Mizorogi F, Inoue T, Sudo K, Ohnishi A. Pharmacokinetics and adverse
events following 5-day repeated administration of lenograstim, a recombinant
human granulocyte colony-stimulating factor, in healthy subjects. Bone Marrow
Transplant 2000; 26: 939–946.
12 Anderlini P, Przepiorka D, Seong D, Miller P, Sundberg J, Lichtiger B et al. Clinical
toxicity and laboratory effects of granulocyte-colony-stimulating factor (ﬁlgrastim)
mobilization and blood stem cell apheresis from normal donors, and analysis of
charges for the procedures. Transfusion 1996; 36: 590–595.
13 Balaguer H, Galmes A, Ventayol G, Bargay J, Besalduch J. Splenic rupture
after granulocyte-colony-stimulating factor mobilization in a peripheral blood
progenitor cell donor. Transfusion 2004; 44: 1260–1261.
14 D’Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating
factor administration: adverse events. Transfus Med Rev 2008; 22: 280–290.
15 Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al.
Adverse events among 2408 unrelated donors of peripheral blood stem cells:
results of a prospective trial from the National Marrow Donor Program. Blood
2009; 113: 3604–3611.
16 Semerad CL, Christopher MJ, Liu F, Short B, Simmons PJ, Winkler I et al. G-CSF
potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone
marrow. Blood 2005; 106: 3020–3027.
17 Winkler IG, Pettit AR, Raggatt LJ, Jacobsen RN, Forristal CE, Barbier V et al.
Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or
AMD3100 have distinct mechanisms of action on bone marrow HSC niches and
bone formation. Leukemia 2012; 26: 1594–1601.
18 Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Levesque JP. Osteoclast-
mediated bone resorption is stimulated during short-term administration of
granulocyte colony-stimulating factor but is not responsible for hematopoietic
progenitor cell mobilization. Blood 1998; 92: 3465–3473.
19 Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating
factor generates epigenetic and genetic alterations in lymphocytes of normal
volunteer donors of stem cells. Exp Hematol 2004; 32: 122–130.
20 Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler A. Changes
in gene expression pattern following granulocyte colony-stimulating factor
administration to normal stem cell sibling donors. Acta Haematol 2007; 117:
68–73.
21 Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid
mobilization of murine and human hematopoietic stem and progenitor cells with
AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307–1318.
22 Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N et al. Rapid mobili-
zation of functional donor hematopoietic cells without G-CSF using AMD3100, an
antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990–998.
23 Bonig H, Chudziak D, Priestley G, Papayannopoulou T. Insights into the biology
of mobilized hematopoietic stem/progenitor cells through innovative
treatment schedules of the CXCR4 antagonist AMD3100. Exp Hematol 2009; 37:
402–415.
24 Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization
of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4
antagonist. Blood 2003; 102: 2728–2730.
25 Foudi A, Jarrier P, Zhang Y, Wittner M, Geay JF, Lecluse Y et al. Reduced retention
of radioprotective hematopoietic cells within the bone marrow microenviron-
ment in CXCR4-/- chimeric mice. Blood 2006; 107: 2243–2251.
26 Rettig MP, Ansstas G, Dipersio JF. Mobilization of hematopoietic stem and
progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012; 26:
34–53.
27 Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase
1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed
or refractory acute myeloid leukemia. Blood 2012; 119: 3917–3924.
28 Dar A, Schajnovitz A, Lapid K, Kalinkovich A, Itkin T, Ludin A et al. Rapid
mobilization of hematopoietic progenitors by AMD3100 and catecholamines is
mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.
Leukemia 2011; 25: 1286–1296.
29 DeMarco SJ, Henze H, Lederer A, Moehle K, Mukherjee R, Romagnoli B et al.
Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4
inhibitors with excellent anti-HIV activity and pharmacokinetic proﬁles. Bioorg
Med Chem 2006; 14: 8396–8404.
30 Balabanian K, Lagane B, Infantino S, Chow KY, Harriague J, Moepps B et al.
The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor
RDC1 in T lymphocytes. J Biol Chem 2005; 280: 35760–35766.
31 Bonig H, Priestley GV, Nilsson LM, Jiang Y, Papayannopoulou T. PTX-sensitive
signals in bone marrow homing of fetal and adult hematopoietic progenitor cells.
Blood 2004; 104: 2299–2306.
32 Bonig H, Priestley GV, Oehler V, Papayannopoulou T. Hematopoietic progenitor
cells (HPC) from mobilized peripheral blood display enhanced migration and
marrow homing compared to steady-state bone marrow HPC. Exp Hematol 2007;
35: 326–334.
33 Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, Frenette PS. PSGL-1
participates in E-selectin-mediated progenitor homing to bone marrow: evidence
for cooperation between E-selectin ligands and alpha4 integrin. Blood 2003; 102:
2060–2067.
34 Szilvassy SJ, Humphries RK, Lansdorp PM, Eaves AC, Eaves CJ. Quantitative
assay for totipotent reconstituting hematopoietic stem cells by a competitive
repopulation strategy. Proc Natl Acad Sci USA 1990; 87: 8736–8740.
35 Harrison DE, Jordan CT, Zhong RK, Astle CM. Primitive hemopoietic stem cells:
direct assay of most productive populations by competitive repopulation with
simple binomial, correlation and covariance calculations. Exp Hematol 1993; 21:
206–219.
36 Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J et al. The
lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1
entry. Nature 1996; 382: 829–833.
37 Fricker SP, Anastassov V, Cox J, Darkes MC, Grujic O, Idzan SR et al. Characterization
of the molecular pharmacology of AMD3100: a speciﬁc antagonist of the G-protein
coupled chemokine receptor, CXCR4. Biochem Pharmacol 2006; 72: 588–596.
POL5551, a novel CXCR4 antagonist
D Karpova et al
9
& 2013 Macmillan Publishers Limited Leukemia (2013) 1–1038 Saini V, Staren DM, Ziarek JJ, Nashaat ZN, Campbell EM, Volkman BF et al. The CXC
chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1alpha
function through distinct receptor interactions. J Biol Chem 2011; 286:
33466–33477.
39 Obrecht D, Chevalier E, Moehle K, Robinson JA. -Hairpin protein epitope mimetic
technology in drug discovery. Drug Discov Today Tech 2012; 9: e63–e69.
40 Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF
receptor in monocytic cells is sufﬁcient to mediate hematopoietic progenitor
mobilization by G-CSF in mice. J Exp Med 2011; 208: 251–260.
41 Ferraro F, Lymperi S, Mendez-Ferrer S, Saez B, Spencer JA, Yeap BY et al. Diabetes
impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl
Med 2011; 3: 104ra101.
42 Liu F, Poursine-Laurent J, Link DC. The granulocyte colony-stimulating factor
receptor is required for the mobilization of murine hematopoietic progenitors
into peripheral blood by cyclophosphamide or interleukin-8 but not ﬂt-3 ligand.
Blood 1997; 90: 2522–2528.
43 Bonig H, Priestley GV, Papayannopoulou T. Hierarchy of molecular-pathway
usage in bone marrow homing and its shift by cytokines. Blood 2006; 107:
79–86.
44 Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, Grabovsky V et al. The
chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature
human CD34(þ) cells: role in transendothelial/stromal migration and
engraftment of NOD/SCID mice. Blood 2000; 95: 3289–3296.
45 Lapidot T, Kollet O. The essential roles of the chemokine SDF-1 and its
receptor CXCR4 in human stem cell homing and repopulation of transplanted
immune-deﬁcient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 2002; 16:
1992–2003.
46 Roberts AW, Foote S, Alexander WS, Scott C, Robb L, Metcalf D. Genetic
inﬂuences determining progenitor cell mobilization and leukocytosis induced by
granulocyte colony-stimulating factor. Blood 1997; 89: 2736–2744.
47 Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A et al.
Pharmacological inhibition of EGFR signaling enhances G-CSF-induced
hematopoietic stem cell mobilization. Nat Med 2010; 16: 1141–1146.
48 Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ.
Mobilization by either cyclophosphamide or granulocyte colony-stimulating
factor transforms the bone marrow into a highly proteolytic environment.
Exp Hematol 2002; 30: 440–449.
This work is licensed under a Creative Commons Attribution 3.0
Unported License. To view a copy of this license, visit http://
creativecommons.org/licenses/by/3.0/
Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)
POL5551, a novel CXCR4 antagonist
D Karpova et al
10
Leukemia (2013) 1–10 & 2013 Macmillan Publishers Limited